Labiotech.eu

News and Trends 12 Mar 2016

What happened this week? 5 Berlin Biotechs, Cancer Infographic, EMA Fast Track

Monday: Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them Tuesday: 5 Biotech Companies you Should know in Berlin Wednesday: EMA Launches its own Fast Track for Breakthrough Therapies Thursday: The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed Friday: Interview: Can this Natural Acid replace Petroleum for the […]

March 12, 2016 - 1 minutemin - By Philip Hemme

News and Trends 12 Mar 2016

Recycling can be Delicious! Austrian BioArt Designers transform Plastic Waste into Edible Mushrooms

You read that right. Austrian designers Katharina Unger and Julia Kaisinger have developed a device that turns polymer waste into edible mushrooms in collaboration with researchers from Utrecht University in the Netherlands. Dinner is served! Take a few seconds to have a look around and count how many items near you have plastic components. From your laptop to […]

March 12, 2016 - 3 minutesmins - By Lourdes Riquelme

News and Trends 11 Mar 2016

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment. This is good news for Genfit, which managed to kickstart a phase III trial for their lead candidate, Elafibranor, just one year after the read-out of the phase IIb results. There […]

March 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 11 Mar 2016

Reviewing Immuno-Oncology: What works and what doesn’t

Researchers from Leiden University Medical Center (LUMC) and ISA Pharmaceuticals (Netherlands) have authored an extensive review of what is working in immuno-oncology – and what hasn’t. The review was accepted in the well-known journal Nature Reviews Cancer and it covers the findings of 250 peer-reviewed papers about immunotherapies. Immuno-oncology is radically changing the way cancer is being […]

March 11, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 11 Mar 2016

Interview: Can this Natural Acid replace Petroleum for the Chemical and Biofuel Industries?

GFBiochemicals in (Italy) is producing levulinic acid (from breakdown of biomass) to replace petroleum-based products for a huge range of sectors, with up to a $30Bn market volume. We had the chance to meet Marcel Van Berkel, the CMO of GFBiochemicals, which is based in Milan with additional Netherlands and Minnesota (US) sites. Berkel told us more about the many […]

March 11, 2016 - 4 minutesmins - By Marie Godar

News and Trends 11 Mar 2016

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

From East to West, this week we say goodbye to Hungary and head up towards Queen Elizabeth II’s United Kingdom. Cambridge, known for its World renowned Academia is where Mission Therapeutics, our Biotech of the Week is located. City: Cambridge (UK) Founded: 2011 Employees: 30 Total raised: €110M (as of 02/2016) CEO: Anker Lundemose Mission: Founded in 2011, Mission Therapeutics, […]

March 11, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 10 Mar 2016

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

Aprea (Sweden) is not a well-know Biotech (yet), but has succeeded in raising €46M from big investors in the US and Europe. Why? For its First-in-class potential for a famous cancer target… Aprea started in 2003 as a spin-off from cancer research at Karolinska Institutet, in its technology-transfer program. This Biotech has a promising candidate […]

March 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 10 Mar 2016

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

This is the story of how the Natural History Museum of Denmark and Molecular Ecology biotech Spygen (France) brought together forensic science techniques to detect traces of Great Crested Newt DNA in UK ponds. The Great Crested Newt (Triturus cristatus) is an amphibian found across Northern Europe and parts of Asia, which has been declining since […]

March 10, 2016 - 3 minutesmins - By Joachim Eeckhout

News and Trends 9 Mar 2016

EMA Launches its own Fast Track for Breakthrough Therapies

The European Medicine Agency (EMA) is launching a priority scheme for therapies addressing unmet medical needs, similar to the FDA’s fast track. The key objective is to help European patients get earlier access to therapies that could be lifesaving, and this could have significant impact on the European Biotech industry. This new PRIME fast-track will include a […]

March 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 9 Mar 2016

Significant doubts about Welsh Government handling of Biotech VC fund

The Wales Life Sciences Fund was intended to attract Biotechs and Pharma to this part of the UK – but the governmental oversight of the establishment of this £50M fund has been criticised in a report by the Wales Audit Office… [Editor’s note: this article was initially published on March 7th, 2016. Due to some inaccuracies, we […]

March 9, 2016 - 3 minutesmins - By Joachim Eeckhout

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What happened this week? 5 Berlin Biotechs, Cancer Infographic, EMA Fast Track

Recycling can be Delicious! Austrian BioArt Designers transform Plastic Waste into Edible Mushrooms

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Reviewing Immuno-Oncology: What works and what doesn’t

Interview: Can this Natural Acid replace Petroleum for the Chemical and Biofuel Industries?

Biotech of the Week: Mission Therapeutics and a Cambridge Pathway against Cancer

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

The Largest Scandinavian Biotech Fundraising of 2016 has just been Signed

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

EMA Launches its own Fast Track for Breakthrough Therapies

Significant doubts about Welsh Government handling of Biotech VC fund

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!